Making the Best of Asthma Management
Produced in collaboration with the Asthma and Allergy Foundation of America.
Support for this educational program was provided by AstraZeneca and Amgen.
Severe asthma can cause people to live in a way to avoid worsening symptoms. Patients facing the challenges of self-management may not understand differences in treatment response or why some treatments can become less effective over time. This can lead to a patient actively deciding not to use treatment or not to follow treatment recommendations, making asthma control more difficult. New agents for severe asthma can help patients better manage their asthma.
Join us for the interactive education, “Breathe Easier with Severe Asthma: The Role of Current and Future Therapies in Reducing Exacerbations and Gaining Control of Your Symptoms.” An expert allergist-immunologist, a patient with asthma, and a representative from the Asthma and Allergy Foundation of America discuss multiple drivers involved in asthma inflammation, current management strategies, and the role of newly available biologic injectable therapies (treatments that use substances made from living organisms to treat disease).
Among the topics discussed include:
How to reduce asthma triggers in your home
Asthma inflammatory subtypes
Epithelium alarmins and their role in asthma
What is a cytokine cascade?
What is inflammatory cycle?
What will my HCP do to identify the asthma phenotype I have?
How do I know if I qualify for a new agent, like tezepelumab?
Side effects of new therapies
Click here to watch on-demand.
Inflammatory Changes that Occur with Asthma
Targeting Asthma with Current and Emerging Treatments
Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
Divisions of Allergy and Immunology
David Geffen School of Medicine at UCLA
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America
Sanaz Eftekhari, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).